DeepMed Research

FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Phase 1

Withdrawn

Conditions: Recurrent Adult Soft Tissue Sarcoma
Stage III Adult Soft Tissue Sarcoma
Adult Synovial Sarcoma
Stage IV Adult Soft Tissue Sarcoma
Myxoid/Round Cell Liposarcoma

Interventions: Biological: Autologous NY-ESO-1-specific CD8-positive T Lymphocytes
Drug: Cyclophosphamide
Other: Laboratory Biomarker Analysis

First Posted Date: 2014-02-11

Last Posted Date: 2016-02-03

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT02059850

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Phase 1

Completed

Conditions: Acute Biphenotypic Leukemia
Previously Treated Myelodysplastic Syndrome
de Novo Myelodysplastic Syndrome
Recurrent Adult Acute Myeloid Leukemia
Untreated Adult Acute Myeloid Leukemia
Secondary Acute Myeloid Leukemia

Interventions: Drug: Cladribine
Drug: Cytarabine
Biological: Filgrastim
Other: Laboratory Biomarker Analysis
Drug: Mitoxantrone Hydrochloride

First Posted Date: 2014-01-24

Last Posted Date: 2020-01-10

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 199

Registration Number: NCT02044796

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Screening Mammography and Latinas: A Multilevel Intervention

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Behavioral: Motivational Interviewing Intervention

First Posted Date: 2013-12-12

Last Posted Date: 2015-07-02

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 540

Registration Number: NCT02010008

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma

Phase 2

Completed

Conditions: Stage IIIC Uveal Melanoma
Stage IIIA Skin Melanoma
Stage IIIB Skin Melanoma
Stage IIIC Skin Melanoma
Stage IV Skin Melanoma
Recurrent Melanoma
Stage IV Uveal Melanoma
Mucosal Melanoma
Recurrent Uveal Melanoma
Stage IIIA Uveal Melanoma

Interventions: Drug: Epacadostat
Biological: MELITAC 12.1 Peptide Vaccine

First Posted Date: 2013-10-11

Last Posted Date: 2018-06-08

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 11

Registration Number: NCT01961115

Locations: 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
University of Virginia Cancer Center, Charlottesville, Virginia, United States

and more 1 locations

Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma

Early Phase 1

Terminated

Conditions: Myxoid Liposarcoma
Synovial Sarcoma
Round Cell Liposarcoma

Interventions: Other: Laboratory Biomarker Analysis
Biological: Recombinant Interferon Gamma

First Posted Date: 2013-10-08

Last Posted Date: 2019-07-10

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 8

Registration Number: NCT01957709

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

MsFLASH-04: Pilot Trial: Telephone Behavioral Therapy for Menopause-related Sleep Disturbance

Not Applicable

Completed

Conditions: Vasomotor Disturbance
Hot Flashes
Menopause
Sleep

Interventions: Behavioral: Cognitive Behavioral Therapy-Insomnia (CBT-I)
Behavioral: Menopause Education Control (MEC)

First Posted Date: 2013-09-06

Last Posted Date: 2015-10-22

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 106

Registration Number: NCT01936441

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States

Associations Between Pre-transplant Comorbidities and Post-transplant Toxicities and Quality of Life

Completed

Conditions: Hematologic Malignancies
Other Diagnoses, Comorbidities, and Complications

First Posted Date: 2013-08-29

Last Posted Date: 2018-01-11

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 252

Registration Number: NCT01930981

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients

Completed

Conditions: Myelodysplastic Syndrome (MDS)
Acute Myeloid Leukemia (AML)

First Posted Date: 2013-08-28

Last Posted Date: 2019-11-15

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 703

Registration Number: NCT01929408

Locations: 🇺🇸
Stanford Cancer Institute, Stanford, California, United States
🇺🇸
University of Maryland, Baltimore, Maryland, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

and more 9 locations

Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies

Phase 1

Completed

Conditions: Refractory Hodgkin Lymphoma
Recurrent Hodgkin Lymphoma
Refractory T-Cell Non-Hodgkin Lymphoma
Recurrent B-Cell Non-Hodgkin Lymphoma
Recurrent T-Cell Non-Hodgkin Lymphoma
Refractory Mantle Cell Lymphoma
Recurrent Mantle Cell Lymphoma
Refractory B-Cell Non-Hodgkin Lymphoma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Carmustine
Drug: Cytarabine
Drug: Etoposide
Other: Laboratory Biomarker Analysis
Drug: Melphalan
Procedure: Peripheral Blood Stem Cell Transplantation
Radiation: Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8

First Posted Date: 2013-08-13

Last Posted Date: 2020-08-04

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 20

Registration Number: NCT01921387

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Chronic GVHD Response Measures Validation

Active, not recruiting

Conditions: Graft vs Host Disease

First Posted Date: 2013-07-18

Last Posted Date: 2025-03-19

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 383

Registration Number: NCT01902576

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy